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Gene expression profiling could assist in revealing
biomarkers of lung cancer prognosis and progres-
sion. The handling of biological samples may strongly
influence global gene expression, a fact that has not
been addressed in many studies. We sought to inves-
tigate the changes in gene expression that may occur
as a result of sample processing time and conditions.
Using Illumina Human WG-6 arrays, we quantified
gene expression in lung carcinoma samples from six
patients obtained at chest opening before and imme-
diately after lung resection with storage in RNAlater
[T1a(CO) and T1b(LR)], after receipt of the sample for
histopathology, placed in RNAlater [T2a(HP)]; snap fro-
zen [T2b(HP.SF)]; or snap frozen and stored for 1 week
[T2c(HP.SFA)], as well as formalin-fixed, paraffin-em-
bedded (FFPE) block samples. Sampling immediately
after resection closely represented the tissue obtained
in situ, with only 1% of genes differing more than
twofold [T1a(CO) versus T1b(LR)]. Delaying tissue har-
vest for an average of 30 minutes from the operating
theater had a significant impact on gene expression,
with approximately 25% of genes differing between
T1a(CO) and T2a(HP). Many genes previously identified
as lung cancer biomarkers were altered during this pe-
riod. Examination of FFPE specimens showed minimal
correlation with fresh samples. This study shows that
tissue collection immediately after lung resection with
conservation in RNAlater is an optimal strategy for gene
expression profiling. (J Mol Diagn 2012, 14:140-148; DOI:
10.1016/j.jmoldx.2011.11.002)
Lung cancer (LC) is the leading cause of cancer death
worldwide1 with non-small cell LC accounting for approx-
imately 87% of newly diagnosed cases.2 LC is the most
common cancer in the UK and it is predicted that it will
remain so for at least the next 20 years.
Measurement of global gene expression is a power-
ful means of establishing the transcriptional activity of
140particular cells or tissues. Gene expression profiling
can allow the identification of subgroups of cancer
allowing early prediction of disease progression and
survival.3–6
Global gene expression studies in LC have had con-
flicting results and many signature-based outcome
predictions have not been replicated independently
(as reviewed7,8). Multiple confounding factors have
hampered these studies including the innate heteroge-
neity of cancerous tissue. Studies are often conducted
with limited numbers of samples making it difficult to
derive statistically stringent results from the measure-
ment of thousands of transcripts.
The quality of the biological sample used and sample
handling are key factors influencing global gene expres-
sion studies. In particular RNA in ex vivo tissues degrades
rapidly with the potential to influence expression patterns
and bias the interpretation of results.
The majority of published gene expression studies
for LC have used tumor tissues that have been snap
frozen or formalin-fixed paraffin embedded (FFPE),
with many of the studies relying on archival or bio-
banked tissues.3–5,9–12 It is uncertain how this material
represents biological features in vivo.
To address the impact of timing of tissue sampling,
processing, and storage, we have conducted a differ-
ential gene expression analysis in lung tumor tissue of
patients with LC at different time points of specimen
collection under various conservation conditions start-
ing from in vivo state represented by viable tissue and
ending at archival FFPE tissue.
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Samples
Lung carcinoma tissue samples were obtained from six
patients during tumor resection surgery at the Royal Bro-
mpton Hospital in London. Demographic and clinical
characteristics of the patients are detailed in Table 1. All
participants gave written informed consent for research
on biobanked tissue and the biobank consent was ap-
proved by the Royal Brompton and Harefield Ethics Com-
mittee (REC reference number LREC 02-261).
Figure 1 illustrates the pipeline for the tissue collection.
When possible for each patient tissue samples were ob-
tained at five collection points: viable tissue at the time of
chest opening [T1a(CO)]; immediately after resection
[T1b(LR)]; after transfer to histopathology [T2a(HP)]; after
transfer to histopathology and snap freezing [T2b(HP.SF)];
and after transfer to histopathology and 1 week after
being snap frozen and archived [T2c(HP.SFA)]. FFPE sam-
ples of each patient’s tumor was obtained from histopa-
thology after tissue had been fixed in 10% formol saline
for 24 hours before being embedded in paraffin wax
according to standard procedure. The FFPE blocks have
been kept at room temperature for 25 to 27 months be-
fore RNA extraction for the current study. The size of
tissue samples taken for the experiment was approxi-
mately 6  6  3 mm. For the FFPE samples, five or six
10-micron sections were obtained.
Table 1. Demographic Characteristics of Study Patients
Patient ID Sex Age at surgery (years
03 Male 57
05 Female 83
06 Male 62
07 Male 70
08 Female 80
09 Male 57Figure 1. Sample collection pipeline.After sampling the T1a(CO), T1b(LR), and T2a(HP) tis-
sues were immediately placed into RNAlater (Qiagen,
Germantown, MD) for 24 hours at 4°C and then frozen at
80°C until RNA extraction. No RNAlater was used for
the T2b(HP.SF) and T2c(HP.SFA) samples as these were
snap frozen.
The average interval of samples collection after
T1a(CO) was 1.9  0.6 hours for T1b(LR), and 2.4  0.5
hours for T2a(HP), T2b(HP.SF), and T2c(HP.SFA). For patients
08 and 09, T2a(HP), T2b(HP.SF), and T2c(HP.SFA) time point
specimens were unavailable.
RNA Extraction
Total RNA was extracted using the RNeasy Fibrous Tis-
sue Mini Kit (Qiagen) for the majority of time points, with
the exception of the FFPE samples processed using the
RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Am-
bion, Foster City, CA). The frozen T1 and T2 specimens
were placed into the lysis buffer at room temperature and
immediately homogenized using the TissueRuptor (hand-
held rotor-stator homogenizer) with disposable probes
(Qiagen) as per the manufacturer’s recommendations.
After homogenization the further steps for RNA extraction
were performed following the manufacturer’s protocol.
Using sterile scalpel blades FFPE sections were cut up
into smaller fragments before RNA extraction according
to the manufacturer’s protocol. Yield and purity of total
Histological diagnosis Tumor stage
Squamous cell carcinoma T2N0M0
Adenocarcinoma T1N0M0
Adenocarcinoma T1N0M0
Broncho-alveolar cell carcinoma T2N0M0
Large cell undifferentiated T2N0M0
Pleomorphic carcinoma T2N1M0)
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spectrophotometer (NanoDrop, Thermo Scientific, Wil-
mington, DE) with RNA integrity determined by RNA In-
tegrity Number (RIN) using a Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA).
Microarray Hybridization
Illumina human WG-6 v2 BeadChip microarrays (contain-
ing 48,804 probes corresponding to 43,186 genes de-
rived from NCBI RefSeq [Build 36.2] and UniGene [Build
199] databases) (Illumina, Inc., San Diego, CA) were
used to assess global gene expression for each sample.
Five hundred nanograms of total RNA was amplified,
converted to cRNA, fragmented, and then biotin-labeled
using the Illumina TotalPrep RNA-amplification kit (Am-
bion, USA). Then 1.5 g of labeled cRNA was hybridized
to each array according to the Illumina whole-genome
gene expression direct hybridization assay protocol
11286331, Rev. A., after which arrays were scanned us-
ing the Illumina BeadArray Reader. The images were
processed and converted into signal intensities using the
Illumina GenomeStudio software Version 2009.2 (Illu-
mina, Inc.). The same software was used to perform
hybridization quality control (QC).
The expression data have been deposited in the
EMBL-EBI Array Express database (http://www.ebi.
ac.uk/arrayexpress) and are available through E-MTAB-
581 accession number.
Statistical Analysis
The signal intensities corresponding to gene expression
levels of individual arrays were background corrected
and imported into text files using the Illumina Ge-
nomeStudio 2009.2 software. All subsequent analyses
were performed in R language environment (R Founda-
tion for Statistical Computing, Vienna, Austria) using the
suite of programs within Bioconductor v.2.5.13
Text files containing gene expression values were im-
ported into R using the lumi package.14 Variance stabi-
lizing normalization was applied to reduce between-ar-
rays variation. The substantial differences in gene
expression between FFPE and other time point samples
required that normalization for FFPE was done sepa-
rately. Post normalization, genes with low detection rates
(P  0.01) were removed. Two datasets were generated
in anticipation of absence of gene expression signal in
FFPE samples due to the high level of RNA degradation
recognized to occur in this type of sample. The first
comprised samples from all time points except FFPE and
included 18,597 genes, each found to be expressed
significantly above background in at least one of these
samples. The second dataset comprised samples from
all time points and included 4555 genes, each found to
be expressed significantly above background in at least
one FFPE sample only. Paired comparisons were per-
formed to assess differentially expressed genes between
all data points. Using the limma package robust regres-
sion was applied and individual t-statistics were calcu-
lated for each gene and each comparison followed byempirical Bayesian method application to moderate the
standard deviations between genes.15 Raw P values
were adjusted for multiple comparisons using the false-
discovery rate approach of Benjamini and Hochberg.16
Hierarchical cluster analysis was applied to datasets to
evaluate the “proximity” between the time points. Using
the publicly available database and research tools
DAVID17,18 and Ingenuity Pathway Analysis (IPA; Inge-
nuity Systems, Redwood City, CA), gene ontology, and
pathway analyses were performed to consider biological
meaning of differential expression of genes between the
data points. In network analysis, maximum 25 networks
and maximum 35 molecules per network were stipulated.
Results
RNA Quality Analysis
High quality of RNA (RIN7) is the ideal to enable robust
expression microarray results to be generated. RINs 7
indicate RNA degradation.
RIN scores revealed that the highest quality of RNA
was obtained for T1a(CO) and T1b(LR) samples: mean 7.4
(range 6.7 to 8.5) and 7.8 (range 6.7 to 8.9), respectively;.
For T2a(HP) samples mean RIN was 7.7 (range 5.4 to 8.3),
whereas for snap-frozen samples [T2b(HP.SF) and
T2c(HP.SFA)] the median values were 4.4 (range 3.3 to 5.6)
and 5.2 (range 4.8 to 5.6), respectively. These figures
highlight the beneficial use of RNAlater stabilization in
preventing RNA degradation. As anticipated, the lowest
RINs, range 2.2 to 2.5, were obtained for FFPE samples.
It is unlikely that poor RINs in T2b(HP.SF) and
T2c(HP.SFA) samples resulted from snap-freezing or long-
term low-temperature storage. It is more likely that RNA
degradation has occurred during the thawing of the
specimens for RNA extraction.19
Despite differences in RNA integrity, the total yield of
RNA was independent of the time points of collection and
ranged between 43 and 367 g (average 198.3 g). For
FFPE samples the yields ranged between 5 and 17 g
(average 8.7 g).
Gene Expression Profiling
The Illumina Human WG-6 v2 BeadChip microarray was
used to analyze whole-genome gene expression in sam-
ples from the six patients.
The average number of genes significantly (P  0.01)
expressed above background was similar at all data
points for unfixed samples and ranged between 12,000
and 13,000 genes. For FFPE samples the expression of
approximately 3000 genes was detected above back-
ground. The highest ratio of average signal to back-
ground was found for T1a(CO) and T1b(LR) samples (av-
erage 3.2  0.8), in other samples it was lower (average
2.7  0.9), and in FFPE it was  1 (average 0.2  0.03).
Two samples were identified as outliers based on the
number of significantly expressed genes and ratio of
signal to background and excluded from subsequent
analyses.
xpressi
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genes were significantly present at least one time point in
non-fixed samples and were included in subsequent
analyses. Exclusion of genes that were not significantly
expressed in at least one of the FFPE samples left 4555
transcripts.
As time from initial chest opening at surgery pro-
gressed there was a notable and significant increase in
the number of genes that were significantly differentially
expressed (Table 2). Less than 5% of genes were differ-
entially expressed between T1a(CO) and T1b(LR) time
points, and only 1% of genes differed more than twofold,
indicating that the T1b(LR) point is a good representation
of the in vivo state. The number of differences between
T1a(CO) or T1b(LR) and subsequent points was much
higher (Table 2).
The T2a(HP), T2b(HP.SF), and T2c(HP.SFA) points were
similar in gene expression (Table 2). The low numbers of
differentially expressed genes between T2a(HP) and
T2b(HP.SF), and between T2b(HP.SF) and T2c(HP.SFA), sug-
gested that snap freezing and storage at low temperature
had a low impact on gene expression. At the same time,
the number of genes differentially expressed between
T1a(CO) or T1b(LR) and T2a(HP) was lower than it was
between T1a(CO) or T1b(LR) and T2b(HP.SF), confirming the
efficiency of RNAlater conservation before freezing.
As expected, FFPE showed most genes to be differ-
entially expressed when compared with the unfixed sam-
ples (Table 2), reflecting a high level of RNA degradation.
Some correlation was observed between gene expres-
sion in T1a(CO) and FFPE samples (R
2 0.12 to 0.45, P 
0.0001, for the 4555 transcripts detectable in FFPE).
We next considered the effects of specimen handling
and processing on the expression of genes previously
established by others as potential markers of LC devel-
opment and prognosis of outcome. We chose 145 genes
that from the literature were reported to be highly relevant
for clinical application as biomarkers4–6 (see Supple-
mental Table S1 at http://jmd.amjpathol.org). Of these
genes, 119 (82%) were significantly expressed in the
tissues of our study and 68 of them were differentially
expressed between T1a(CO)/T1b(LR) and later time points
Table 2. Number and Percentage of Significant Differentially Exp
Chest
opening
Lung
resection
Histo-p
RNA la
T1a(CO) T1b(LR) T2a(H
T1a(CO) – 914 (4.9) 4508 (2
T1b(LR) 334/580 – 4378 (2
T2a(HP) 1560/2948 1881/2497 –
T2b(HP.SF) 1411/3952 1623/3537 13/66
T2c(HP.SFA) 1363/4801 1797/4527 108/57
FFPE 527/3645 475/3635 448/36
The total number of differentially expressed genes (FDR-adjusted, P
measured given in parentheses. Percentage was calculated using a t
embedded tissue (FFPE). For FFPE, the denominator was the 4555 genes
increased expression is shown before “/”and the number decreased in e
immediately prior.(Table 3).4–6Cluster Analysis of Gene Expression
We performed a non-supervised hierarchical cluster
analysis to identify genes characterizing each of the
times studied. Considering the 661 genes that differed
significantly across T1a(CO) to T2c(HP.SFA) (FDR-adjusted
P  0.0001), we observed that the specimens collected
in the operating theater [T1a(CO) and T1b(LR)] clustered
together and were distinct from a second cluster based
around retrieval during routine histopathology proce-
dures [T2a(HP), T2b(HP.SF), and T2c(HP.SFA)] (Figure 2).
When we considered transitions across all time points
between T1a(CO) to FFPE (including 3700 genes that
were statistically significant at FDR-adjusted P  0.0001)
it was obvious that FFPE samples differed markedly from
all other time points (Figure 2).
Gene Ontology and Pathway Analyses
To consider the possible biological meaning of changes
in gene expression between time points we performed
gene ontology (GO) and pathway analyses. We restricted
these analyses to genes differentially expressed between
T1a(CO) and later time points with FDR-adjusted P  0.01
(Table 4).
Two marginally statistically significant GO terms were
found for genes differentially expressed between the ear-
liest time points [T1a(CO) and T1b(LR)] (Table 4). These
related to the inflammatory response and the response to
wounding.
For genes differentially expressed in the transition be-
tween T1a(CO) and downstream time points [T2a(HP),
T2b(HP.SF), and T2c(HP.SFA)] the top GO terms obtained
were similar for all comparisons and mainly characterized
biopolymer and macromolecule metabolism. This was
most likely a reflection of the activation and depression of
cell reactions to lack of external supplements.
Finally, statistically significant GO terms for transition
between T1a(CO) and FFPE time points were found to
encompass metabolic and biosynthesis processes,
translation, and ribosome structure. These all likely reflect
the tissue activity in the period after resection and before
fixation in formalin.
We then performed a database-derived pathway anal-
Genes Between Different Time Points
Histo-path
snap frozen
Histo-path snap
frozen and stored
T2b(HP.SF) T2c(HP.SFA) FFPE
5363 (28.8) 6164 (33.1) 4172 (91.6)
5160 (27.7) 6324 (34.0) 4110 (90.2)
79 (0.4) 684 (3.7) 4083 (89.6)
– 32 (0.2) 4030 (88.5)
18/14 – 4071 (89.4)
400/3630 405/3666 –
is given above the central diagonal, with the percentage of total genes
18,579 genes for all time points except for formalin-fixed and paraffin
asurable transcripts. Beneath the diagonal the number of genes showing
on is shown after “/”. Subsequent time points are compared with the oneressed
ath
ter
P)
4.2)
3.5)
6
35
 0.05)
otal of
with meysis using genes that were at least threefold differentially
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JMD March 2012, Vol. 14, No. 2Table 3. Genes Previously Considered as Potential Biomarkers of Lung Cancer Prognosis and Survival4–6 Found to be Significantly Differentially
Expressed in Transition Between in Situ After Chest Opening or Lung Resection (T1a(CO)/T1b(LR)) and Later Time Points
Gene ID Gene name Fold change*
AASS Aminoadipate-semialdehyde synthase 1.95
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 1.54
ADM Adrenomedullin 1.10
AKAP12 A kinase (PRKA) anchor protein 12 1.13
ALDOA Aldolase A, fructose-bisphosphate 1.34
ALG8 Asparagine-linked glycosylation 8, alpha-1,3-glucosyltransferase homolog (S. cerevisiae) 1.19
C6ORF15 Chromosome 6 open reading frame 15 0.89
CASK Calcium/calmodulin-dependent serine protein kinase (MAGUK family) 1.49
CASP4 Caspase 4, apoptosis-related cysteine peptidase 1.52
CDS1 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 1.48
COL3A1 Collagen, type III, alpha 1 1.40
CPA3 Carboxypeptidase A3 (mast cell) 3.42
CRK V-crk sarcoma virus CT10 oncogene homolog (avian) 2.19
CSTB Cystatin B (stefin B) 0.72
CTSL Cathepsin L1 1.63
DBP D site of albumin promoter (albumin D-box)-binding protein 0.81
DPAGT1 Dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1
(GlcNAc-1-P transferase)
1.43
EVI1 MDS1 and EVI1 complex locus 3.20
FADD Fas (TNFRSF6)-associated via death domain 1.63
FEZ2 Fasciculation and elongation protein zeta 2 (zygin II) 0.81
FGFR2 Fibroblast growth factor receptor 2 2.01
FLJ20397 HEAT repeat-containing 2 1.45
FUCA1 Fucosidase, alpha-L- 1, tissue 0.83
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 1.33
GGA3 Golgi-associated, gamma adaptin ear containing, ARF-binding protein 3 1.34
GRB7 Growth factor receptor-bound protein 7 1.46
H2AFZ H2A histone family, member Z 1.03
HLA-G Major histocompatibility complex, class I, G 0.56
HLF Hepatic leukemia factor 0.68
HMBS Hydroxymethylbilane synthase 1.50
HRB ArfGAP with FG repeats 1 1.62
KIAA0746 Sel-1 suppressor of lin-12-like 3 (C. elegans) 1.65
KLF10 Kruppel-like factor 10 2.10
KLF6 Kruppel-like factor 6 0.78
KRTDAP Keratinocyte differentiation-associated protein 1.06
LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 1.52
MAP4 Microtubule-associated protein 4 1.34
MAPK14 Mitogen-activated protein kinase 14 2.19
MSH3 MutS homolog 3 (E. coli) 1.32
MT2A Metallothionein 2A 0.77
NME2 Non-metastatic cells 2, protein (NM23B) expressed in 1.52
NP Purine nucleoside phosphorylase 1.45
NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 0.43
NTS Neurotensin 12.57
PDE7A Phosphodiesterase 7A 1.13
PELI2 Pellino homolog 2 (Drosophila) 1.29
PPIF Peptidylprolyl isomerase F 1.37
RAB11A RAB11A, member RAS oncogene family 1.11
RND3 Rho family GTPase 3 1.31
RPLP0 Ribosomal protein, large, P0 1.45
RPS26 Ribosomal protein S26 1.49
RPS3 Ribosomal protein S3 1.56
SC4MOL Sterol-C4-methyl oxidase-like 0.78
SFTPC Surfactant protein C 0.50
SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 1 2.83
SPRR2E Small proline-rich protein 2E 1.28
STARD3 StAR-related lipid transfer (START) domain-containing 3 0.92
STC1 Stanniocalcin 1 0.64
TIA1 TIA1 cytotoxic granule-associated RNA-binding protein 1.78
TKTL1 Transketolase-like 1 0.29
TMEM126B Transmembrane protein 126B 1.37
TMF1 TATA element modulatory factor 1 2.04
TPBG Trophoblast glycoprotein 1.39
TTR Transthyretin 0.76
TUBA4A Tubulin, alpha 4a 0.64
UGP2 UDP-glucose pyrophosphorylase 2 1.39
WNT10B Wingless-type MMTV integration site family, member 10B 0.51
ZNF552 Zinc finger protein 552 1.11*Calculated as median value for all pair-wise comparisons, FDR-adjusted P  0.05.
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and T2c(HP.SFA) time points with an FDR-adjusted P 
0.001. There were 295 out of the 386 genes correspond-
ing to these criteria that were successfully mapped in IPA
and used for the pathway analysis. The top bio-functions
that characterized interaction networks contained several
terms and molecules related to cancer (Table 5), indicat-
Figure 2. Clusters of the most statistically significant (FDR adjusted P 
0.0001) differentially expressed genes. A: A heat map and hierarchical cluster
analysis of 661 genes differentially expressed (P  0.0001) at two surgical
and three histopathology lab sample times. B: A heat map and hierarchical
cluster of 3700 genes detectable in the FFPE samples and differentially
expressed (P  0.0001) compared with earlier time points.
Table 4. Top Gene Ontology (GO) Terms for Genes Differential
(T1a(CO)), and Other Time Points
Time point GO ID
Lung resection GO:0006954 Inflam
GO:0009611 Resp
Routine Histopathology
(RNAlater)*
GO:0034960
GO:0006139
Cellu
Nucl
ac
FFPE GO:0006412
GO:0044237
GO:0003735
Tran
Cellu
Struc*For routine histopathology, only the RNAlater point is shown, as the results aing that tissue handling significantly influences gene ex-
pression related to the phenotype of interest. Examination
of canonical pathways revealed significant numbers of
differentially expressed genes to be related to innate
immunity and inflammation. These effects were mediated
mainly by tumor necrosis factor (TNF) and IL-6 cytokines
or associated with the FOS oncogene.
We used a further IPA analysis to test how well FFPE
samples might represent in vivo gene expression, con-
centrating on the 383 genes that were not differentially
expressed between T1a(CO) and FFPE (FDR-adjusted
P  0.05). A total of 163 genes were successfully
mapped in IPA. Only two weakly significant pathways
were revealed for these genes; FGF signaling (P  0.03;
FGF17, PIK3C2B, and FGF18 proteins) and TR/RXR ac-
tivation (P 0.035; PIK3C2B, NXPH2, RCAN2). This sug-
gested that the FFPE samples provided very limited in-
formation compared to earlier time points.
Discussion
Given the increasing importance of microarray profiling
for clinical cancer management, it is perhaps surprising
that there is little published information examining the
effect of time of collection, tissue handling and storage on
global gene expression analysis in LC and other solid
tumors.
Our investigations suggest some simple guidelines for
optimal management of lung tumor specimens and gene
expression studies.
Tissue obtained in situ in the chest [T1a(CO)] may be
considered as a gold standard, but in situ harvest may not
always be practical or feasible. We found sampling im-
mediately after resection [T1b(LR)] closely represented
the in vivo state, as only 193 (1%) of genes differed more
than twofold between T1a(CO) and T1b(LR) and genes
related to cancer did not appear in network and path-
ways analyses.
The second major stage in handling of tumor speci-
mens typically occurs in histopathology departments. We
found that an average transition time of 30 minutes from
the operating theater had a significant impact on gene
expression profiles, as we observed differences in ex-
pression for approximately 25% of genes (or more than
5% if at least twofold changes were counted) when either
T1a(CO) or T1b(LR) were compared with T2a(HP).
essed in Transition Between in Situ Biopsy After Chest Opening
Term P value
y response 0.014
o wounding 0.049
polymer metabolic process
, nucleoside, nucleotide and nucleic
bolic process
4.29  109
1.00  105
tabolic process
onstituent of ribosome
1.97  107
4.64  106
7.95  106ly Expr
mator
onse t
lar bio
eobase
id meta
slation
lar me
tural cre very similar to snap-frozen samples.
3.
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significant impact on RNA quality and integrity, resulting
in lower expression signals (but no additional bias in
gene expression patterns). Storage after freezing did not
significantly affect gene expression scores because few
genes were differentially expressed between T2b(HP.SF)
and T2c(HP.SFA) time points.
FFPE samples have been considered to be a promis-
ing source of biological information because of their
availability.20 A number of studies have been published
in which the capability of FFPE samples to provide RNA
of adequate quality for expression assays in cancer with
use of real-time polymerase chain reaction and different
microarray platforms in comparison with snap frozen ma-
terial has been analyzed.9,11,12,21,22 Overall there was a
poor correlation between FFPE and snap frozen tissues in
our study, although a limited set of genes demonstrated
correlation that might be useful in particular circum-
stances. It has also been shown that the time of FFPE
samples storage is critical, with samples older than 1
year have remarkably decreased RNA quality.12 Our cur-
rent study of approximately 2-year-old FFPE samples has
shown that the number of genes significantly expressed
above background was four times lower than in non-FFPE
samples. This suggests that the potential of FFPE sam-
ples to represent an in vivo state is circumscribed. These
results however may have been influenced by the use of
oligo(dT) primers in the cDNA synthesis step in the Illu-
mina optimized TotalPrep RNA-amplification kit protocol.
A proportion of the RNA from FFPE samples is likely to be
fragmented with species present that lack polyA tails.
Consequently, the TotalPrep RNA-amplification kit that is
required to be used in combination with the Illumina Hu-
man WG-6 v2 BeadChip microarrays may for FFPE sam-
ples result in a lower yield of target cRNA. Recently it has
been proposed that using Affymetrix Exon 1.0ST arrays
(Affymetrix, Santa Clara, CA), originally designed to allow
study of alternative splicing, may be important when
dealing with archival FFPE samples. The probe sets on
Table 5. Top IPA bio-functions of gene networks characterizing
routine histopathology laboratory (T2a(HP))
Bio-functions
Diseases and Disorders
Inflammatory response
Dermatological diseases and conditions
Cancer
Hematological disease
Organismal injury and abnormalities
Molecular and Cellular Functions
Cell-to-cell signaling and interaction
Cellular movement
Cellular growth and proliferation
Cell death
Cell cycle
Physiological System Development and Function
Hematological system Development and function
Immune cell trafficking
Tissue development
Tissue morphology
Organ developmentthe exon arrays instead of targeting the 3= end of eachtranscript span the entire length of each gene. This may
allow the potential to detect and measure more robustly
in archival FFPE RNA more genes within the genome.23
Inflammatory response and related pathways medi-
ated mainly by TNF and IL-6 molecules were highly af-
fected by sample handling in transition between T1a(CO)/
T1b(LR) and later time points. TNF and IL-6 are pluripotent
cytokines involved in regulation of immune responses
and inflammation. They have been found to be essential
in the development and clinical heterogeneity of cancer
as well as other lung diseases such as asthma and
chronic obstructive pulmonary disease (COPD).24–28 In
particular, IL6 is considered as one of the key genes
involved in the development and progression of LC
through up-regulation of the EGFR/IL-6/STAT3 signaling
cascade29 and the potential utility of anti-IL-6 therapy in
cancer has been discussed.30
We also found that pathways associated with the FOS
oncogene to be up-regulated in the transition from T1 to
T2 time points. Human FOS acts as a trans-activating
regulator of gene expression and has an important role in
signal transduction, cell proliferation, and differentiation
in early response of cells to growth factors.31–33
Global gene expression assays are considered to be a
promising tool to improving our understanding of etiology
and pathogenesis of LC and may be of use in screening,
disease classification, and outcome prediction.7 Our ob-
servation that many genes previously considered to be
biomarkers for LC development and prognosis4–6 were
affected by the time and handling of samples indicate
that the accuracy and standardization of gene expres-
sion measurements is essential for clinical applications of
the technology. Our observations also highlight the need
for caution, with regard to the reproducibility and utility for
meta-analyses of data from some microarray-based gene
expression studies, especially those where snap-frozen
samples have been used and others where fresh sam-
ples have not been immediately processed. A significant
number of highly cited articles on gene expression pro-
nsition between samples harvested at operation (T1a(CO)) or the
P value Number of molecules
18  109 – 2.42  103 51
46 108 – 2.29  103 30
12  106 – 2.38  103 79
25  106 – 2.28  103 16
25  106 – 2.28  103 25
52  109 – 2.49  103 55
12  109 – 2.42  103 48
80  106 – 2.28  103 70
87  106 – 2.42  103 69
25  106 – 2.16  103 26
52 109 – 2.42  103 54
52  109 – 2.42  103 35
52  109 – 2.28  103 42
08  106 – 2.29  103 38
79  106 – 2.16  103 11the tra
1.
7.
2.
8.
8.
1.
3.
1.
2.
3.
1.
1.
1.
2.filing in lung or breast cancer involved studies where
Sample Handling and Gene Expression 147
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studies have reported predictive expression signatures,
but there has been little if any overlap in particular genes
between the studies.34,35 Even though the studies differ
in many methodological aspects, as shown by our cur-
rent study, tissue handling has a significant influence on
gene expression profiles obtained. It is worth noting that
the quality of samples for microarray experiments is not a
lung cancer specific issue and is increasingly recognized
to be a crucial consideration in studies of other cancer
types and noncancerous tissues.36–38
There are a few additional points to highlight about our
study. The sample size of our study is small (n  6) and
therefore the study statistically may be underpowered
and potentially lead to bias in results due to outliers. We
have at least partially addressed this by using robust
regression to calculate differential expression. This ap-
proach is claimed to be more powerful and less sensitive
to outliers than a number of other statistical proce-
dures.39 Another issue arises from using samples of dif-
ferent histological types. This produces additional heter-
ogeneity in gene expression profiles and can reduce the
number of genes differentially expressed between the
conditions. Even though this cannot be excluded, we
presume that the initial heterogeneity pattern is kept
throughout the experiment and overall results are unlikely
significantly affected. Also, according to our unpublished
data, different cancer subtypes share a significant number
of common genes underlying common cancer-related pro-
cesses, such as inflammation or cell cycle. This means that
we can expect a lot of similarity in global gene expression
profiles for different lung cancer subtypes despite the pres-
ence of subtype specific expression signatures.
In summary, our study demonstrates that sample han-
dling and processing are critical factors when conduct-
ing and interpreting results for LC gene expression pro-
filing. Tissue collection for gene expression analysis at
lung resection with conservation in RNAlater is the opti-
mal strategy for gene expression profiling.
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